Furthermore, our analysis of multiple clinical datasets revealed that METTL3 is associated with NSCLC prognosis, providing evidence for METTL3 as a promising biomarker for prognosis of NSCLC. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.